RRM2 and renal carcinoma: We previously analyzed a TKI resistance dataset (GSE76068) from a mouse model and showed that RRM2 is closely associated with sunitinib resistance in renal cancer, and this effect is mediated by its activation of the AKT signaling pathway 28.